New technology aids in prostate cancer treatment
2010 June
Researchers at Queen’s have developed a new way of performing lab tests that
could improve the way doctors manage prostate cancer treatment. It will allow
them to identify with unprecedented accuracy losses of a gene called PTEN that
is associated with an aggressive group of prostate cancers.
The improved Fluorescence In-Situ Hybridization (FISH) platform uses DNA probes to analyze the three-dimensional space cancer cells occupy in routine clinical microscopic analysis of tissue sections of tumors. It will provide a more accurate way of identifying PTEN loss in biopsies and tissue sections so doctors can better match the type and amount of treatment to the aggressiveness of a tumor.
0